Key result
Anti-α-actinin immunostaining reliably identifies rod-bearing fibers in 100% of sporadic late-onset nemaline myopathy cases.
Why the study?
Sporadic late-onset nemaline myopathy is a treatable or fatal condition, but its diagnosis remains challenging and therapeutic consensus has not been achieved.
Observational (n=17)
No
Answers are grounded in this paper and cite their sources.
Anti-α-actinin immunostaining is a reliable pathologic marker for SLONM, and patients may respond favorably to ASCT or combined immunotherapy.
BACKGROUND AND OBJECTIVES: Sporadic late-onset nemaline myopathy (SLONM) is a treatable or otherwise fatal myopathy. Diagnosis of SLONM is still challenging, and no therapeutic consensus has been achieved. Here, we reported the clinicopathologic features and long-term follow-up data of SLONM in a Chinese cohort. METHODS: We performed a retrospective evaluation of clinical, pathologic, and treatment outcomes of 17 patients with SLONM diagnosed between March 1986 and April 2021 at our neuromuscular center. Immunohistochemistry (IHC) with antibodies against 5 Z-disc-associated proteins was performed in the muscle biopsies of SLONM to identify a potential pathologic marker in aid of diagnosis. In comparison, we also performed muscle IHC in patients with selective type II fiber atrophy (n = 22), neurogenic atrophy (n = 22), mitochondrial myopathy (n = 5), immune-mediated necrotizing myopathy (n = 5), and normal controls (n = 5). RESULTS: Most of the patients exhibited asymmetric limb muscles weakness (71%, 12/17) and neck extensor weakness (53%, 9/17). Immunofixation electrophoresis was performed in 11 patients, and 4 of them were identified with monoclonal gammopathy of undetermined significance (MGUS). EMG from 16 patients demonstrated a myopathic pattern with spontaneous activities in 69% (11/16) of them. Muscle MRI showed preferential involvement of paraspinal, gluteus minimus and medius, semimembranosus, and soleus muscles. Suspected nemaline bodies on modified Gomori trichrome were confirmed by IHC using anti-α-actinin antibody (100%, 17/17), anti-myotilin antibody (94%, 16/17), anti-desmin antibody (94%, 16/17), anti-α-B crystallin antibody (65%, 11/17), and anti-telethonin antibody (18%, 3/17) with various positive rates. Notably, anti-α-actinin IHC showed the highest percentage of strongly positive staining (77%, 13/17), being the only one without negative results. Moderate improvement following autologous stem cell transplantation (ASCT) was noted in 3/4 patients with MGUS; favorable outcomes were also achieved in 6/7 patients without MGUS, including 3 patients with complete recovery who were given a combined treatment of prednisone and another immunosuppressant. DISCUSSION: SLONM is a treatable myopathy with ASCT or traditional immunotherapy, especially when combined with steroids and immunosuppressants. Anti-α-actinin immunostaining is the most reliable pathologic marker to identify rod-bearing fibers, and it should be performed routinely in adult patients with undiagnosed nonnecrotic myopathies.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) conducted an observational in Sporadic late-onset nemaline myopathy (n=17). Anti-α-actinin immunostaining and immunotherapy vs. Other Z-disc-associated protein immunostaining (diagnostic); unexposed (clinical) was evaluated on Positive identification of rod-bearing fibers (nemaline bodies) on immunohistochemistry. Anti-α-actinin immunostaining reliably identified rod-bearing fibers in 100% of sporadic late-onset nemaline myopathy cases, outperforming other markers for diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: